Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma...
– Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) – Asia market represents one of the largest HepC virus carrier populations in the world BOTHELL, WA,...
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis)...
Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics®, today announces expansion of space and testing capabilities in their international network of accredited LabPMM® clinical laboratories. Additions to the...
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the initiation of a Phase 1,...
A clinical trial, coordinated by researchers from Queen Mary University of London, is currently recruiting patients in London to see whether a new cholesterol-lowering drug could save lives in people who are intolerant to statins. Cardiovascular disease is the number...
Email
Text